NephroDI Therapeutics, Inc.

Pharmaceutical company · Seattle, Washington, United States

NephroDI Therapeutics, Inc. is a pharmaceutical company headquartered in Seattle, Washington, United States. Its earliest recorded incorporation is in 2017. It has received 2 US government small-business research awards (SBIR/STTR) from health agencies, $1.4 million in total, most recently in 2025. It has reported private securities offerings to the US SEC, most recently $2 million sold in a notice filed in 2024.

Profile compiled from public records. Is this your company? Request a correction or update

NephroDI Therapeutics at a glance

Typepharmaceutical company
HeadquartersSeattle, Washington, United States
Earliest incorporation on record2017
Employees (self-reported, 2025)5
SEC CIK1840655

What does NephroDI Therapeutics do?

US government research funding

2 SBIR/STTR small-business research awards from US health agencies, $1.4 million in total (2020 to 2025). NIH funding came from the National Institute of Diabetes and Digestive and Kidney Diseases.

Private fundraising reported to the SEC

2 Form D notices; the most recent reported $2 million sold (2024).

Frequently asked questions about NephroDI Therapeutics

Where is NephroDI Therapeutics headquartered?

NephroDI Therapeutics, Inc. is headquartered in Seattle, Washington, United States.

What does NephroDI Therapeutics do?

NephroDI Therapeutics, Inc. is a pharmaceutical company.

When was NephroDI Therapeutics founded?

The earliest incorporation on record for NephroDI Therapeutics, Inc. is in 2017, according to public company registers.

Similar companies

Need a CRO or CDMO for your next study?

Compare transparent quotes from research and manufacturing partners, then contract once. Free for buyers.

Compare quotes

Last updated 2026-09-25. Data licences